Risk factors
Cadrenal Therapeutics (CVKD) risk factors
Item 1A of every Cadrenal Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks9 new2 dropped19 reworded
Accumulated deficit reached $39.0 million with cash insufficient for the next twelve months, threatening going concern status.
Filed Mar 31, 2026 - FY2024 10-K risk factors71 risks
Clinical-stage biopharmaceutical company dependent entirely on the success and regulatory approval of its sole product candidate, tecarfarin. Requires substantial additional capital to fund upcoming pivotal Phase 3 clinical trials and secure manufacturing. Operates with a limited history and relies heavily on third-party contractors for clinical trials and supply.
Filed Mar 13, 2025